IOL Radio welcomes Barbara Hamilton, MD, Chief of Interventional Radiology at Desert Regional Medical Center in Palm Springs, California. Dr. Hamilton is a former Chair of the Society of Interventional Radiology’s Women in IR section, and author of the blog, "The Tired Superheroine." She is here today to discuss her recent book, "Save Lives, Enjoy Your Own."

Learn more Dr Hamilton here.

In this episode, our guests discuss the results of the TARGET study, which was presented at SIR in March 2021. Dr Riad Salem, Chief of Vascular and Interventional Radiology at Northwestern Medicine, speaks with Professor Marnix Lam, one of the principal investigators of the TARGET study and Professor of Nuclear Medicine and Chief of Nuclear Medicine at the University Medical Center Utrecht.

Learn more about Dr Salem, Prof Lam, and the TARGET study here.

This episode of IOL Radio features Dr Jason Levy, Interventional Radiologist at Northside Hospital in Atlanta, Georgia and lead investigator of the OPuS One trial. This trial studied the quality of life outcomes from a global, prospective, nonrandomized, multicenter study of radiofrequency ablation using Medtronic’s OsteoCool™ RF Ablation System for the palliative treatment of patients with painful osseous metastases. Dr Levy discusses the out-to-12-months outcomes he presented at the Society of Interventional Radiology (SIR) 2021 meeting.

IOL Radio speaks with Dr Joseph J Busch, Jr and Kathy Busch, from the Busch Center, a clinic in Alpharetta, Georgia that is dedicated to the screening, diagnosis, and treatment of prostate cancer. Earlier this year, the clinic added Profound Medical’s TULSA system to its treatment options. Dr Busch and Kathy discuss how TULSA has impacted their clinical procedures and patient outcomes.

Learn more about the Busch Center here.

In this episode, IOL Radio speaks with Jason Levy, MD, lead investigator of OPuS One, a study done on the outcomes of the first 100 patients treated with the OsteoCool™ System. The OsteoCool™ RF Ablation System is a cooled radiofrequency ablation technology that offers simultaneous dual-probe capabilities for treating painful bone tumors. The OPuS One Study was published in the November 2020 edition of the Journal of Vascular and Interventional Radiology (JVIR). This ongoing, multicenter, post-market study is the largest prospective study on radiofrequency ablation for bone metastases.

You can view the transcript for this podcast episode here.

In this episode of IOL Radio, we speak with Dr Albert DeNittis, a radiation oncologist at Lankenau Cancer Center in Wynnewood, Pennsylvania. Dr Dennitis is here to discuss NuView Life Science’s VPAC1, a peptide platform that detects the over expression of specific receptors that appear only on the surface of malignant cells for early diagnosis and therapy of cancer.

You can view a transcript of this episode here.

In this episode of IOL Radio, we discuss the results of the LEGACY Study, a robust multicenter study confirming Boston Scientific’s TheraSphere™ as a neoadjuvant or standalone therapy in treating hepatocellular carcinoma. 

Our guest host is Dr Nora Tabori, an Interventional Radiologist at MedStar Washington Hospital Center in Washington DC, and a member of the Society of Interventional Radiology. She is joined by Dr Riad Salem, the principal investigator of the LEGACY Study. Dr Salem is a Professor of Radiology, Medicine, and Surgery, Chief of the Section of Vascular and Interventional Radiology, and Vice-Chairman of Image-Guided Therapy at the Department of Radiology at Northwestern University in Chicago, Illinois.

You can read the transcript of this podcast here.